432 related articles for article (PubMed ID: 30117378)
1. Performance of tumor testing for Lynch syndrome identification in patients with colorectal cancer: A retrospective single-center study.
Signoroni S; Tibiletti MG; Ricci MT; Milione M; Perrone F; Pensotti V; Chiaravalli AM; Carnevali I; Morabito A; Bertario L; Vitellaro M
Tumori; 2019 Feb; 105(1):76-83. PubMed ID: 30117378
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Colorectal and Endometrial Microsatellite Instability Tumor Analysis and Premm
Mannucci A; Furniss CS; Ukaegbu C; Horiguchi M; Fehlmann T; Uno H; Yurgelun MB; Syngal S
J Clin Oncol; 2020 Dec; 38(34):4086-4094. PubMed ID: 32997573
[TBL] [Abstract][Full Text] [Related]
3. Molecular testing for Lynch syndrome in people with colorectal cancer: systematic reviews and economic evaluation.
Snowsill T; Coelho H; Huxley N; Jones-Hughes T; Briscoe S; Frayling IM; Hyde C
Health Technol Assess; 2017 Sep; 21(51):1-238. PubMed ID: 28895526
[TBL] [Abstract][Full Text] [Related]
4. Assessment of Tumor Sequencing as a Replacement for Lynch Syndrome Screening and Current Molecular Tests for Patients With Colorectal Cancer.
Hampel H; Pearlman R; Beightol M; Zhao W; Jones D; Frankel WL; Goodfellow PJ; Yilmaz A; Miller K; Bacher J; Jacobson A; Paskett E; Shields PG; Goldberg RM; de la Chapelle A; Shirts BH; Pritchard CC;
JAMA Oncol; 2018 Jun; 4(6):806-813. PubMed ID: 29596542
[TBL] [Abstract][Full Text] [Related]
5. The proportion of endometrial tumours associated with Lynch syndrome (PETALS): A prospective cross-sectional study.
Ryan NAJ; McMahon R; Tobi S; Snowsill T; Esquibel S; Wallace AJ; Bunstone S; Bowers N; Mosneag IE; Kitson SJ; O'Flynn H; Ramchander NC; Sivalingam VN; Frayling IM; Bolton J; McVey RJ; Evans DG; Crosbie EJ
PLoS Med; 2020 Sep; 17(9):e1003263. PubMed ID: 32941469
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathologic Comparison of Lynch Syndrome-associated and "Lynch-like" Endometrial Carcinomas Identified on Universal Screening Using Mismatch Repair Protein Immunohistochemistry.
Mills AM; Sloan EA; Thomas M; Modesitt SC; Stoler MH; Atkins KA; Moskaluk CA
Am J Surg Pathol; 2016 Feb; 40(2):155-65. PubMed ID: 26523542
[TBL] [Abstract][Full Text] [Related]
7. Comparison of screening strategies for Lynch syndrome in patients with newly diagnosed endometrial cancer: a prospective cohort study in China.
Chao X; Li L; Wu M; Ma S; Tan X; Zhong S; Bi Y; Lang J
Cancer Commun (Lond); 2019 Jul; 39(1):42. PubMed ID: 31307542
[TBL] [Abstract][Full Text] [Related]
8. Identification of HNPCC by molecular analysis of colorectal and endometrial tumors.
Vasen HF; Hendriks Y; de Jong AE; van Puijenbroek M; Tops C; Bröcker-Vriends AH; Wijnen JT; Morreau H
Dis Markers; 2004; 20(4-5):207-13. PubMed ID: 15528786
[TBL] [Abstract][Full Text] [Related]
9. Feasibility of screening for Lynch syndrome among patients with colorectal cancer.
Hampel H; Frankel WL; Martin E; Arnold M; Khanduja K; Kuebler P; Clendenning M; Sotamaa K; Prior T; Westman JA; Panescu J; Fix D; Lockman J; LaJeunesse J; Comeras I; de la Chapelle A
J Clin Oncol; 2008 Dec; 26(35):5783-8. PubMed ID: 18809606
[TBL] [Abstract][Full Text] [Related]
10. Tumor testing to identify lynch syndrome in two Australian colorectal cancer cohorts.
Buchanan DD; Clendenning M; Rosty C; Eriksen SV; Walsh MD; Walters RJ; Thibodeau SN; Stewart J; Preston S; Win AK; Flander L; Ouakrim DA; Macrae FA; Boussioutas A; Winship IM; Giles GG; Hopper JL; Southey MC; English D; Jenkins MA
J Gastroenterol Hepatol; 2017 Feb; 32(2):427-438. PubMed ID: 27273229
[TBL] [Abstract][Full Text] [Related]
11. Molecular analysis of Iranian colorectal cancer patients at risk for Lynch syndrome: a new molecular, clinicopathological feature.
Zeinalian M; Emami MH; Salehi R; Naimi A; Kazemi M; Hashemzadeh-Chaleshtori M
J Gastrointest Cancer; 2015 Jun; 46(2):118-25. PubMed ID: 25722176
[TBL] [Abstract][Full Text] [Related]
12. Association of tumor morphology with mismatch-repair protein status in older endometrial cancer patients: implications for universal versus selective screening strategies for Lynch syndrome.
Rabban JT; Calkins SM; Karnezis AN; Grenert JP; Blanco A; Crawford B; Chen LM
Am J Surg Pathol; 2014 Jun; 38(6):793-800. PubMed ID: 24503759
[TBL] [Abstract][Full Text] [Related]
13. PREMM5 distinguishes sporadic from Lynch syndrome-associated MMR-deficient/MSI-high colorectal cancer.
Sandoval RL; Horiguchi M; Ukaegbu C; Furniss CS; Uno H; Syngal S; Yurgelun MB
Fam Cancer; 2023 Oct; 22(4):459-465. PubMed ID: 37572151
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the clinical prediction model PREMM(1,2,6) and molecular testing for the systematic identification of Lynch syndrome in colorectal cancer.
Kastrinos F; Steyerberg EW; Balmaña J; Mercado R; Gallinger S; Haile R; Casey G; Hopper JL; LeMarchand L; Lindor NM; Newcomb PA; Thibodeau SN; Syngal S;
Gut; 2013 Feb; 62(2):272-9. PubMed ID: 22345660
[TBL] [Abstract][Full Text] [Related]
15. BRAF mutation analysis is a valid tool to implement in Lynch syndrome diagnosis in patients classified according to the Bethesda guidelines.
Molinari F; Signoroni S; Lampis A; Bertan C; Perrone F; Sala P; Mondini P; Crippa S; Bertario L; Frattini M
Tumori; 2014; 100(3):315-20. PubMed ID: 25076244
[TBL] [Abstract][Full Text] [Related]
16. Early-onset colorectal cancer patients without family history are "at very low risk" for lynch syndrome.
Stigliano V; Sanchez-Mete L; Martayan A; Diodoro M; Casini B; Sperduti I; Anti M
J Exp Clin Cancer Res; 2014 Jan; 33(1):1. PubMed ID: 24383517
[TBL] [Abstract][Full Text] [Related]
17. Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer.
Pérez-Carbonell L; Ruiz-Ponte C; Guarinos C; Alenda C; Payá A; Brea A; Egoavil CM; Castillejo A; Barberá VM; Bessa X; Xicola RM; Rodríguez-Soler M; Sánchez-Fortún C; Acame N; Castellví-Bel S; Piñol V; Balaguer F; Bujanda L; De-Castro ML; Llor X; Andreu M; Carracedo A; Soto JL; Castells A; Jover R
Gut; 2012 Jun; 61(6):865-72. PubMed ID: 21868491
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and Clinical Implications of Mismatch Repair-Proficient Colorectal Cancer in Patients With Lynch Syndrome.
Ranganathan M; Sacca RE; Trottier M; Maio A; Kemel Y; Salo-Mullen E; Catchings A; Kane S; Wang C; Ravichandran V; Ptashkin R; Mehta N; Garcia-Aguilar J; Weiser MR; Donoghue MTA; Berger MF; Mandelker D; Walsh MF; Carlo M; Liu YL; Cercek A; Yaeger R; Saltz L; Segal NH; Mendelsohn RB; Markowitz AJ; Offit K; Shia J; Stadler ZK; Latham A
JCO Precis Oncol; 2023 May; 7():e2200675. PubMed ID: 37262391
[TBL] [Abstract][Full Text] [Related]
19. Lynch syndrome pre-screening and comprehensive characterization in a multi-center large cohort of Chinese patients with colorectal cancer.
Li Y; Fan L; Zheng J; Nie X; Sun Y; Feng Q; Lian S; Bai W; Cai W; Yang Y; Su B; Xi Y; Lin D
Cancer Biol Med; 2022 Jun; 19(8):1235-48. PubMed ID: 35638907
[TBL] [Abstract][Full Text] [Related]
20. The proportion of endometrial cancers associated with Lynch syndrome: a systematic review of the literature and meta-analysis.
Ryan NAJ; Glaire MA; Blake D; Cabrera-Dandy M; Evans DG; Crosbie EJ
Genet Med; 2019 Oct; 21(10):2167-2180. PubMed ID: 31086306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
